HUMA
Humacyte IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$188.16M
P/E Ratio
—
EPS
$-0.26
Beta
2.10
52W High
$2.93
52W Low
$0.55
50-Day MA
$0.90
200-Day MA
$1.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.81
PEG Ratio
—
About Humacyte Inc
Humacyte Inc (HUMA) is a pioneering biotechnology company dedicated to revolutionizing vascular and regenerative medicine through the development of innovative human acellular vessels (HAVs). Focusing on urgent clinical needs for vascular reconstruction and chronic disease treatment, Humacyte provides off-the-shelf solutions designed to improve patient outcomes and lower healthcare costs. With its advanced technology platform, the company is poised to drive significant advancements in transplantation and tissue engineering, positioning itself as a leader in the evolving landscape of medical therapies.
Fundamentals
| Revenue (TTM) | $2.04M |
| Gross Profit (TTM) | $-76.37M |
| EBITDA | $-100.09M |
| Operating Margin | -6603.00% |
| Return on Equity | -249.80% |
| Return on Assets | -52.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.02 |
| Price-to-Book | 60.52 |
| Price-to-Sales (TTM) | 92.33 |
| EV/Revenue | 99.37 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $222.02M |
| Float | $190.86M |
| % Insiders | 14.15% |
| % Institutions | 25.45% |
Historical Volatility
HV 10-Day
101.32%
HV 20-Day
92.54%
HV 30-Day
130.25%
HV 60-Day
124.28%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($5.10 target)
2
Strong Buy4
Buy1
HoldData last updated: 4/29/2026